These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2138477)

  • 21. [French FAC vs FEC study in advanced breast cancer].
    Keiling R; Armand PP; Hurteloup P; Cappelaere P
    Onkologie; 1986 Aug; 9 Suppl 1():8-10. PubMed ID: 3528969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly dose adriamycin as first line chemotherapy in advanced breast cancer.
    Jönsson PE; Malmberg M; Ericsson M; Ryden S
    Anticancer Res; 1991; 11(2):877-9. PubMed ID: 2064346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
    Hoogstraten B; George SL; Samal B; Rivkin SE; Costanzi JJ; Bonnet JD; Thigpen T; Braine H
    Cancer; 1976 Jul; 38(1):13-20. PubMed ID: 947510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vindesine-mitoxantrone (VM) versus vindesine-4'-epidoxorubicin (VE) in metastatic breast cancer: a prospective randomized trial.
    Hausmaninger H; Lehnert M
    Onkologie; 1988 Feb; 11(1):59-60. PubMed ID: 3283629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
    Findlay BP; Walker-Dilks C
    Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly CAF chemotherapy for advanced breast cancer patients.
    Hwang WS; Hsiung CA; Ko WS; Wang CC; Chang JY; Lai GM; Hsieh RK; Tsao CJ; Chen LT; Law CK; Cheng AL; Fan SF; Tzeng CH; Chiou TJ; Whang-Peng J
    Oncology; 1997; 54(4):293-7. PubMed ID: 9216853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
    Gu X; Jia S; Wei W; Zhang WH
    Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
    Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
    Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
    Namer M; Soler-Michel P; Turpin F; Chinet-Charrot P; de Gislain C; Pouillart P; Delozier T; Luporsi E; Etienne PL; Schraub S; Eymard JC; Serin D; Ganem G; Calais G; Maillart P; Colin P; Trillet-Lenoir V; Prevost G; Tigaud D; Clavère P; Marti P; Romieu G; Wendling JL
    Eur J Cancer; 2001 Jun; 37(9):1132-40. PubMed ID: 11378344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
    Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
    Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
    Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
    Delozier T; Vernhes JC
    Bull Cancer; 1991 Nov; 78(11):1013-25. PubMed ID: 1369547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
    Wenzel C; Locker GJ; Pluschnig U; Zielinski CC; Rudas M; Oberhuber G; Gnant MF; Taucher S; Jakesz R; Steger GG
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):155-9. PubMed ID: 12172982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly-dose doxorubicin (WDA) in advanced breast cancer.
    Sigurdsson H; Johansson-Terje I; Aspegren K; Landberg T; Andersson T; Borgström S; Thelin AM
    Radiother Oncol; 1986 Oct; 7(2):133-9. PubMed ID: 3786819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly chemotherapy in advanced prostatic cancer.
    Francini G; Petrioli R; Manganelli A; Cintorino M; Marsili S; Aquino A; Mondillo S
    Br J Cancer; 1993 Jun; 67(6):1430-6. PubMed ID: 8512828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
    Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
    Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
    Cersosimo RJ; Hong WK
    J Clin Oncol; 1986 Mar; 4(3):425-39. PubMed ID: 3005521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
    Heidemann E; Steinke B; Hartlapp J; Schumacher K; Possinger K; Kunz S; Neeser E; von Ingersleben G; Hossfeld D; Waldmann R
    Onkologie; 1990 Feb; 13(1):24-7. PubMed ID: 2186320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.